Explore tweets tagged as #compstatins
Delighted to have co-hosted the @NIH workshop on 'Innate Immunity During #SARSCoV2 and #COVID19' w/ @Baric_Lab & Jenny Ting @UNC Insightful talks by 21 speakers and excellent science! Complement modulation and C3 targeting w/ #compstatins was discussed by @dmastellos @NIAIDNews
1
2
11
Antonio Risitano in a tour-de-force of how the #PNH #hematology field was reshaped over the last 15 ys advancing from anti-C5 therapy to #C3-targeted inhibition w/ #compstatins History in the making... 14th International @AegeanConf of #ComplementTherapeutics #Rhodes
0
0
8
What a day to remember! The 16th International @AegeanConf Conference on #ComplementTherapeutics is dedicated to the pioneering work and groundbreaking contributions of @LambrisJD to #complementbiology & drug discovery #compstatins Happy 70th John!! What an inspiring journey!
1
4
26
Scientists from @UniBasel_en, @PennMedicine, @UniLeipzig and @UniUtrecht provide molecular insights into the mode-of-action of the compstatin family of complement inhibitors. #compstatins, #therapeutics
@RicklinLab, @LambrisJD and @ChristinaLamers
https://t.co/wMyIjeGAFa
0
8
9
Elated to see our 2nd gen compstatin-based C3 inhibitor find its way to patients with GA, an inflammatory ocular disease with such a huge burden! Remarkable news and a great thrust to continue improving compstatins!
1
8
30
Translating research results into tangible therapies that can change patients' lives to the better....is at the core of our research endeavors. So glad to have been able to witness the full-fledged transformation of compstatins from therapeutic leads to clinically approved
0
3
15
Our latest review on the #compstatin class of clinical #C3 inhibitors now out @TrendsinPharma! With insights on #structure-#activity, #mode of action #PK/#PD aspects & the emerging therapeutic potential of #compstatins in chronic neurodegenerative diseases https://t.co/4BxNzz31P6
1
5
16
The first heart #xenotransplantation is a game-changer! Back in 1999 we showed with Tom Mollnes that #compstatins can block hyperacute #rejection prolonging survival of perfused pig #xenograft Later on this effect was recapitulated in pig hearts w/ Cp40! https://t.co/pdqQFfqoi6
0
1
13
The long history of compstatins in this space starts back in 2006 when analog 4(1MeW)7W (Cp05) was licensed by the University of Pennsylvania to Potentia (now Apellis) for clinical development in both dry and neovascular AMD See also this video for more:
1
0
2
A huge milestone for C3-targeted therapy that vindicates the science we invested behind the discovery of compstatins Proud that a 2nd generation #compstatin analog has shown efficacy and superiority over Soliris in PNH patients" This is exciting news for complement therapeutics!
We are excited to share positive top-line results from our Phase 3 PEGASUS trial evaluating pegcetacoplan (APL-2), an investigational targeted C3 therapy, in adults with paroxysmal nocturnal hemoglobinuria (PNH). Read more here: https://t.co/n04FoPipx2
#PNH #raredisease
2
9
22
@TrendsinPharma The approval of #pegcetacoplan, a 2nd gen compstatin-based C3 inhibitor in 2021 serves as critical validation of C3-targeted treatment. This review traces the #evolution of compstatins from their academic 'roots' to the clinic and highlights current and future clinical directions
0
0
5
A long-debated issue in the field of #complement_therapeutics now addressed with facts and figures: Reis et al @Penn report the safety and immune profile of non-human primates under prolonged C3 inhibition @ImmunologyNews @LambrisLab @Amyndas #compstatins
https://t.co/XrGx0V3mSU
0
4
2
Complement C3 as a Target of Host Modulation in #Periodontitis: Following validation in NHP models of periodontal #inflammation, C3 inhibition moves to the bedside #complementbiology #oralcavity #dysbiosis #therapeutics #compstatins #AMY101
1
2
5
Compstatins: the dawn of clinical C3-targeted complement inhibition, online now, review article from Christina Lamers, Dimitrios C. Mastellos, Daniel Ricklin and John D. Lambris. @ChristinaLamers @dmastellos @LambrisJD @NCSR_Demokritos @PennPathLabMed
0
8
10
Oral dysbiotic inflammation and #periodontal_disease in the crosshairs of #complement_therapeutics #C3 #compstatins #periodontitis #complementbiology
0
1
2
Insightful comment by Karpman, Bekassy, @palheox & @roumenina on the prospects of therapeutic complement #C3 inhibition in #AMR and kidney #transplantation #ComplementTherapeutics #compstatins
https://t.co/EuuDlCrWeE
2
6
9
Worth checking out in @FrontImmunol: Anti-complement treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for proximal complement inhibition? #PNH #eculizumab #C3inhibitors #compstatins #FD #FB #complement_therapeutics #clinicalTrials
0
2
6
Our review on the clinical promise of next-generation #complement #therapeutics is now published in @NatRevDrugDisc Real pleasure developing this story with Dan #Ricklin @UniBasel and the 'father' of #compstatins Prof John Lambris @LambrisLab @PennMedicine
5
12
17
We greatly appreciate @NIH's support, our "Gold" sponsor since 1990s, which made the development of #compstatins possible. Stay tuned as the compstatin family grows.
Basic @NIH-funded research has led to the development of many new drugs. For example, in the 1990s, NIH-supported research on the #complement system, part of the #ImmuneSystem, led to the discovery of #compstatin, a compound that inhibits a key complement protein called C3.
0
3
13